Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
The #ALS space—and the HEALEY ALS Platform Trial—saw two more failures this week, from Denali Therapeutics and AbbVie/Calico Life Sciences. After a disappointing 2024 for the space ...
Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...
Zacks.com on MSN4d
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
The multi-centre, placebo-controlled, double-blind trial will assess the therapy’s safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients. Sean M Healey & AMG Centre for ...
failed to show efficacy in part of the phase 2/3 HEALEY ALS basket trial, causing a fall in its share price. The South San Francisco biotech announced that eIF2B agonist DNL343 was unable to slow ...
The multi-centre, placebo-controlled, double-blind trial will assess the therapy’s safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients. Sean M Healey & AMG Centre for ALS ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Governor Maura Healey announced a bond bill filed Tuesday that will be the largest proposed infrastructure investment in Massachusetts’ public higher education system in decades. An Act to Build ...
Gov. Maura Healey filed a $2.5 billion borrowing bill Tuesday that would dump cash into Massachusetts’ public higher education system to update aging infrastructure that the first-term Democrat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback